-transparent.png){kind=logo}
In the therapy of metastatic breast cancer MAP was used with different dosages and different forms of administration. Pharmacokinetics and pharmacodynamics were investigated. MAP plasma concentrations are dose dependent with great interindividual variation. The cortisol suppressive effect is dependent on plasma concentrations with only narrow interindividual variability. The oral administration of the crystal suspension is equivalent to the administration of tablets concerning plasma levels und endocrine effects. The therapy schedule for i.m. application used here leads to lower MAP plasma concentrations and correspondingly to a minor endocrine effect than in oral therapy. Tumor effective and cortisol suppressive plasma concentrations seem to have the same level.
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
January 1986,
Breast cancer research and treatment,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
January 1995,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
January 1991,
Gynakologische Rundschau,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
June 1986,
Cancer treatment reports,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
September 1982,
Cancer treatment reports,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
May 1989,
Cancer,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
January 1985,
Cancer chemotherapy and pharmacology,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
June 1988,
Cancer,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
January 1995,
Anticancer research,
H C Blossey, and
H E Wander, and
G A Nagel, and
J Köbberling, and
U Kleeberg
June 1984,
Australian and New Zealand journal of medicine,
